Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFMW) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Sunshine Biopharma (SBFMW) over the last 12 years, with Q3 2025 value amounting to $295951.0.

  • Sunshine Biopharma's Net Income towards Common Stockholders rose 12470.78% to $295951.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 876.46%. This contributed to the annual value of -$5.1 million for FY2024, which is 1393.84% down from last year.
  • Per Sunshine Biopharma's latest filing, its Net Income towards Common Stockholders stood at $295951.0 for Q3 2025, which was up 12470.78% from -$3.0 million recorded in Q2 2025.
  • Sunshine Biopharma's Net Income towards Common Stockholders' 5-year high stood at $667116.0 during Q4 2021, with a 5-year trough of -$23.5 million in Q4 2022.
  • For the 5-year period, Sunshine Biopharma's Net Income towards Common Stockholders averaged around -$2.8 million, with its median value being -$1.3 million (2024).
  • In the last 5 years, Sunshine Biopharma's Net Income towards Common Stockholders plummeted by 362447.18% in 2022 and then soared by 12470.78% in 2025.
  • Over the past 5 years, Sunshine Biopharma's Net Income towards Common Stockholders (Quarter) stood at $667116.0 in 2021, then tumbled by 3624.47% to -$23.5 million in 2022, then soared by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then skyrocketed by 113.71% to $295951.0 in 2025.
  • Its Net Income towards Common Stockholders was $295951.0 in Q3 2025, compared to -$3.0 million in Q2 2025 and -$1.2 million in Q1 2025.